Strengthen your sinus surgery action plan with the
PROPEL™ family of implants
PROPEL™ sinus implants feature an innovative 2-in-1 mechanism that maintains the surgical opening following sinus surgery while delivering mometasone furoate, a potent corticosteroid, directly to the sinus mucosa where it is needed1-3.
OPEN in the sinus cavity
- Self-expanding design that opens in and supports the sinus cavity1
- Non-obstructive design allows for nasal clearance and the delivery of topical rinses1
- Dissolvable frame over approximately 30-45 days after placement as the sinus cavity heals5
DELIVERS Mometasone furoate (MF) locally
- Delivers 370µg of MF over 30 days
- MF present in the mucosal tissue for up to 60 days4 (based on pre-clinical data)
Mometasone furoate delivers a combination of potency and safety
Mometasone furoate was selected for use in PROPEL™ implant for its sinonasal drug characteristics7:
Highly lipophilic - Readily absorbs into tissue
Targeted + potent - High glucocorticoid receptor affinity
Low systemic bioavailability - Minimizes systemic effects
Drug characteristics comparison6-9
* Lipophilicity numbers normalized relative to triamcinolone acetonide.
† As measured by relative receptor binding affinity compared to dexamethasone, which is set to a value of 100. Higher values designate greater potency.
‡ As measured by plasma concentration of drug from intranasal vs intravenous route.
References
1
PROPEL™ [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2013.
2
PROPEL™ Mini [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
3
PROPEL™ Contour [Instructions for Use]. Menlo Park, CA: Intersect ENT; 2016.
4
Li PM, Downie D, Hwang PH. Controlled steroid delivery via bioabsorbable stent: safety and performance in a rabbit model. Am J Rhinol Allergy. 2009;23(6):591-596.
5
Murr AH,et al. Int Forum Allergy Rhinol. 2011;1:23–32. REF-10007.
6
Lemke T, Williams D, Roche V, Zito SW, eds. Foye’s Principles of Medicinal Chemistry. 6th ed. Balitmore, MD: Lippincott Williams & Wilkins; 2008.
7
Winkler J, Hochhaus G, Derendorf H. How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(4):356-363.
8
Sastre J, Mosges R. Local and systemic safety of intranasal corticosteroids. J Investig Allergol Clin Immunol. 2012;22(1):1-12.
9
PubChem. Dexamethasone. https://pubchem.ncbi.nlm.nih.gov/compound/Dexamethasone. Accessed June 24, 2019.
UC202311003EE MPM – 12526 Rev. 1.0
CRS, chronic rhinosinusitis; MF, mometasone furoate.
See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at cema.medtronic.com.
PROPEL™ Important Safety Information:
The PROPEL™ sinus implants are intended to maintain patency and locally deliver steroid to the sinus mucosa in patients ≥18 years of age following sinus surgery: PROPEL™ for the ethmoid sinus, PROPEL™ Mini for the ethmoid sinus/frontal sinus opening, and PROPEL™ Contour for the frontal sinus ostia in chronic rhinosinusitis patients. Contraindications include patients with intolerance to mometasone furoate (MF) or hypersensitivity to bioabsorbable polymers. Safety and effectiveness of the implant in pregnant or nursing females have not been studied. Risks may include, but are not limited to, pain/pressure, displacement of the implant, possible side effects of intranasal MF, sinusitis, epistaxis, and infection. For full prescribing information see IFU at www.intersectENT.co.uk. For use by healthcare professionals only.
Important Reminder: This information is intended only for users in markets where Medtronic products and therapies are approved or available for use as indicated within the respective product manuals. Content on specific Medtronic products and therapies is not intended for users in markets that do not have authorization for use.
PROPEL™ and PROPEL™ Mini:
PROPEL™ Contour:
